Celiac Disease Foundation, Provention Bio partner on mAb therapeutic

By The Science Advisory Board staff writers

October 7, 2020 -- The Celiac Disease Foundation has partnered with Provention Bio to provide clinical trial recruitment for the ongoing phase IIB Proactive Celiac Study, which is testing the safety and efficacy of PRV-015, an anti-interleukin-15 monoclonal antibody (mAb).

The study began enrolling patients in August 2020 in the U.S. and plans to recruit patients from Canada later in the year. The foundation will leverage its full suite of patient recruitment services to enroll 220 adults with celiac disease who continue to experience symptoms while following a gluten-free diet.

PRV-015 is designed to block interleukin-15, a cytokine that plays a key role in celiac disease, creating inflammation and intestinal damage. Previous studies have shown that PRV-015 reduces gluten-induced symptoms and markers of intestinal inflammation.

Provention Bio, Amgen begin mAb trial for celiac disease
Provention Bio has begun a phase IIB study of PRV-015, an anti-interleukin-15 monoclonal antibody (mAb), in adult patients with nonresponsive celiac disease....
Microbe-based platform aims for sweet spot between biologics and gene therapy
A microbe-based therapeutics platform that has been in development for nearly 30 years is gaining traction for the treatment of inflammatory and autoimmune...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter